Market Intelligence, Clinical Progress, and High-Purity Reagents for p53-Reactivation Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MDM2/HDM2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | MDM2 (HDM2) Full-Length Recombinant Protein, His-Tag; High purity (>95%), RING domain intact, Sequence Verified, Endotoxin <1EU/µg. | View MDM2 Products |
| Antigen (Mutant) | MDM2 C464A (Ligase Dead) Mutant Protein; Cys-to-Ala mutation in RING domain abolishes E3 ligase activity; Critical negative control for ubiquitination assays. | View MDM2 Products |
| Interaction Partner | p53 (TP53) Tumor Suppressor Protein; DNA-Binding Domain (DBD, aa 94-312) or Full-Length; Sequence Verified for PPI assays. | View TP53 Products |
| Counter-Screen | MDM4 (MDMX) Recombinant Protein; Close homolog for selectivity testing of dual vs. MDM2-specific inhibitors. | View MDM4 Products |
| Gene Delivery | MDM2 Promise-ORF Lentivirus; Full-length ORF (NM_002392) with CMV promoter and Puromycin selection for stable cell line construction. | View MDM2 Products |
| Validator | MDM2 siRNA Set (3 unique sequences); For target specificity verification and rescue experiments. | View MDM2 Products |
| Upstream Regulator | p14ARF (CDKN2A) Protein; Alternative reading frame protein that directly inhibits MDM2 E3 ligase activity. | View CDKN2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| MDM2-p53 PPI Disruption (FP/TR-FRET) | Purified MDM2 (aa 1-491) and p53 DBD (>95% purity, theoretical MW verified); Suitable for fluorescence polarization binding assays. |
| E3 Ligase Activity (Auto-ubiquitination) | Wild-type MDM2 with intact RING domain; C464A ligase-dead mutant included as negative control (Sequence Verified). |
| MDM4/MDMX Selectivity Screening | Human MDM4 homolog protein available for parallel counter-screening; Strict sequence verification ensures no cross-reactivity in antibody assays. |
| Platelet Toxicity Modeling | Human and Mouse MDM2 ortholog proteins available for species-specific toxicity correlation (thrombocytopenia assessment). |
| False Positive Control | Validated siRNA and C464A mutant protein included for mechanistic verification of inhibitor specificity. |
Live MDM2/HDM2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MDM2/HDM2 therapeutics is shifting from monotherapy in solid tumors to combination strategies in hematologic malignancies. As first-generation Nutlins faced dose-limiting thrombocytopenia, the next wave of R&D is targeting platelet-sparing derivatives and MDM2-specific versus dual MDM2/MDM4 inhibitors. The clinical pivot toward AML and MDS—where TP53 wild-type status is more prevalent—demands robust cellular assays that distinguish p53-dependent versus off-target cytotoxicity. Major players include Roche (idasanutlin), Rain Therapeutics (milademetan), Novartis (siremadlin), and Kartos Therapeutics (navtemadlin).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Nutlins) | Roche, Rain Therapeutics, Novartis, Kartos Therapeutics | Liposarcoma, AML/MDS | High-purity MDM2/p53 proteins for FP/SPR-based PPI disruption |
| Stapled Peptide | Aileron Therapeutics (ALRN-6924) | Solid Tumors (p53 WT) | Cell permeability assays using MDM2 stable cell lines (Lentivirus) |
| PROTAC/Degrader | Arvinas, Kymera Therapeutics, C4 Therapeutics | Hematologic Malignancies | Ternary complex formation (MDM2-Ligase) + ubiquitination assays (WT vs C464A) |
| Molecular Glue / Dual Inhibitors | Kevlar Therapeutics (navtemadlin) | Refractory Cancers | MDM4 selectivity panel (Homolog proteins for counter-screening) |
Key Differentiation Factors & Assay Strategy
- Affinity & Kinetics: Inhibitors must bind the hydrophobic p53-binding pocket of MDM2 with high affinity to competitively displace p53.
- Selectivity: Distinguish MDM2 from its homolog MDM4 (MDMX); some strategies target dual inhibition, others require high selectivity.
- Safety: Reduce on-target/off-tumor hematological toxicity (thrombocytopenia).
- Mechanism: For PROTACs, validate ternary complex (POI-Linker-MDM2) formation and ubiquitination efficiency.
Related Targets
- TP53 (p53): Direct binding partner and downstream effector of MDM2.
- MDM4 (MDMX): Homolog target for selectivity counter-screening; often forms heterodimers with MDM2.
- CDKN2A (p14ARF): Upstream regulator that directly inhibits MDM2 E3 ligase activity.